Attenuated Infectious Hematopoietic Necrosis Virus with Rearranged Gene Order as Potential Vaccine.
The genome of infectious hematopoietic necrosis virus (IHNV), a salmonid novirhabdovirus, has been engineered to modify the gene order and to evaluate the impact on a possible attenuation of the virus in vitro and in vivo By reverse genetics, eight recombinant IHNVs (rIHNVs), termed NxGy according to the respective positions of the nucleoprotein (N) and glycoprotein (G) genes along the genome, have been recovered. All rIHNVs have been fully characterized in vitro for their cytopathic effects, kinetics of replication, and profiles of viral gene transcription. These rIHNVs are stable through up to 10 passages in cell culture. Following bath immersion administration of the various rIHNVs to juvenile trout, some of the rIHNVs were clearly attenuated (N2G3, N2G4, N3G4, and N4G1). The position of the N gene seems to be one of the most critical features correlated to the level of viral attenuation. The induced immune response potential in fish was evaluated by enzyme-linked immunosorbent spot assay (ELISPOT) and seroneutralization assays. The recombinant virus N2G3 induced a strong antibody response in immunized fish and conferred 86% of protection against wild-type IHNV challenge in trout, thus representing a promising starting point for the development of a live attenuated vaccine candidate.


OBJECTIVE
In Europe, no vaccines are available against infectious hematopoietic necrosis virus (IHNV), one of the major economic threats in fish aquaculture. Live attenuated vaccines are conditioned by a sensible balance between attenuation and pathogenicity. Moreover, nonsegmented negative-strain RNA viruses (NNSV) are subject to a transcription gradient dictated by the order of the genes in their genomes. With the perspective of developing a vaccine against IHNV, we engineered various recombinant IHNVs with reordered genomes in order to artificially attenuate the virus. Our results validate the gene rearrangement approach as a potent and stable attenuation strategy for fish novirhabdovirus and open a new perspective for design of vaccines against other NNSV.
VIM, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
Ronan N
RN
Rouxel
VIM, INRA, Université Paris-Saclay, Jouy-en-Josas, France.|Animal Health Research Center (CISA-INIA), Valdeolmos, Madrid, Spain.
Carolina
C
Tafalla
VIM, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
Emilie
E
Mérour
Animal Health Research Center (CISA-INIA), Valdeolmos, Madrid, Spain.
Esther
E
Leal
VIM, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
Stéphane
S
Biacchesi
VIM, INRA, Université Paris-Saclay, Jouy-en-Josas, France michel.bremont@jouy.inra.fr.
Michel
M
Brémont
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D005393:Fish Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D015870:Gene Expression; D023061:Gene Order; D016679:Genome, Viral; D029142:Infectious hematopoietic necrosis virus / Q000235:genetics* / Q000276:immunology* / Q000502:physiology; D007700:Kinetics; D017686:Oncorhynchus mykiss; D018353:Rhabdoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology; D014774:Virulence / Q000235:genetics; D014779:Virus Replication / Q000235:genetics
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines
Recent Pat DNA Gene Seq. 2013 Apr 1;7(1):62-5
22670604
Biochem Biophys Res Commun. 2013 Sep 6;438(4):619-23
23939047
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3501-6
9520395
J Virol. 2003 Jan;77(1):732-8
12477878
J Virol. 2000 Dec;74(23):11247-53
11070023
J Virol. 2000 Sep;74(17):7895-902
10933697
Cell. 1985 May;41(1):259-67
2986844
J Virol. 2010 Jul;84(14):7140-50
20463070
Cell. 1981 Feb;23(2):477-84
6258804
Methods. 2001 Dec;25(4):402-8
11846609
J Virol. 2010 Apr;84(8):4002-12
20130065
Int Immunol. 2002 Apr;14(4):411-9
11934877
J Virol. 2000 Aug;74(16):7261-9
10906180
J Virol. 1984 Feb;49(2):303-9
6319730
J Virol. 1999 Jun;73(6):4705-12
10233930
J Virol. 2002 Mar;76(6):2881-9
11861855
Clin Chem. 2009 Apr;55(4):611-22
19246619
Fish Shellfish Immunol. 2003 Jul;15(1):39-50
12787686
J Virol. 2003 Oct;77(20):11201-11
14512568
J Virol. 2003 May;77(10):5740-8
12719567
Virology. 2015 May;479-480:379-92
25864107
J Virol. 1985 Feb;53(2):469-76
3838192
J Gen Virol. 1990 Mar;71 ( Pt 3):561-7
1690259
Curr Top Microbiol Immunol. 2004;283:61-119
15298168
Dis Aquat Organ. 2003 Aug 4;55(3):205-10
13677506
Proc Natl Acad Sci U S A. 1976 May;73(5):1504-8
179088
J Virol. 2001 Jul;75(13):6107-14
11390612
PLoS One. 2013 Dec 06;8(12 ):e82737
24324826